Abstract
Twenty-two patients with hairy cell leukemia were treated with biosynthetic (recombinant) α-2-interferon in an open-label, single-arm efficacy study. Patients received 2 x 106 U/m2 recombinant α2-interferon three times weekly. Therapy was well tolerated subjectively with minimal short-term hematologic toxicity. Two patients had bacterial infections during the period of study, and one patient experienced a short-lived readily reversible rejection of a corneal transplant. Statistical comparison of the mean hematologic indices at study entry and after three to six months of therapy with recombinant α-2-interferon indicates a significant improvement in hemoglobin, granulocyte, and platelet counts. Bone marrow biopsies in six of 14 patients after six months of therapy showed a > 50% decrease in the infiltration of leukemia cells. We conclude that recombinant α-2-interferon is highly effective therapy for hairy cell leukemia.
Original language | English (US) |
---|---|
Pages (from-to) | 1017-1020 |
Number of pages | 4 |
Journal | Blood |
Volume | 65 |
Issue number | 4 |
DOIs | |
State | Published - 1985 |
Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology